Anti-human VEGF (Bevacizumab Biosimilar)

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody shares the same variable regions as the therapeutic antibody Bevacizumab, making it ideal for research use. It specifically binds to human VEGF (vascular endothelial growth factor), a 45 kDa homodimeric, disulfide-linked glycoprotein that plays a central role in angiogenesis, vasculogenesis, and endothelial cell proliferation. VEGF promotes mitogenesis, chemotaxis, and increases vascular permeability. Because angiogenesis is essential for tumor growth and metastasis, VEGF has become a major therapeutic target in cancer treatment. Bevacizumab functions by neutralizing VEGF activity—blocking its interaction with VEGF receptors on endothelial cells, thereby inhibiting the formation of new blood vessels and suppressing tumor progression. This Bevacizumab biosimilar is suitable for in vitro studies of VEGF inhibition, tumor angiogenesis, and related signaling pathways, providing a valuable tool for cancer and vascular biology research.

Specifications

Product name: Anti-human VEGF (Bevacizumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894728

Molecular Weight: 150 kDa